EZH2 and diffuse large B-cell lymphoma: Further, the EZH1 and EZH2 dual inhibitor valemetostat (DS-3201b) had antitumor activities in both ABC and GCB DLBCL cells in vitro, which is now under investigation in a phase I trial for advanced NHL including DLBCL [135].